Edgewise Therapeutics (EWTX) News Today $26.26 -0.46 (-1.72%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Rises By 8.9%Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 6,140,000 shares, a growth of 8.9% from the December 15th total of 5,640,000 shares. Approximately 9.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 837,700 shares, the days-to-cover ratio is presently 7.3 days.January 19 at 3:34 AM | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. lifted its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 146.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 158,506 shares of the company's stock after buying an additional 94,147 shares duriJanuary 18 at 3:11 AM | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1% - Time to Sell?Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.1% - Time to Sell?January 16, 2025 | marketbeat.comEdgewise Therapeutics: Strategic Positioning and Promising Clinical Advancements Support Buy RatingJanuary 15, 2025 | markets.businessinsider.comPiper Sandler Remains a Buy on Edgewise Therapeutics (EWTX)January 15, 2025 | markets.businessinsider.comTruist Financial Remains a Buy on Edgewise Therapeutics (EWTX)January 15, 2025 | markets.businessinsider.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 7.4% - What's Next?Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.4% - Still a Buy?January 14, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $43.17 Average PT from BrokeragesJanuary 14, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)January 13, 2025 | markets.businessinsider.comEdgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025January 13, 2025 | stockhouse.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Buy" from AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among brokerages thaJanuary 11, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What HappenedEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What HappenedJanuary 6, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 100,000 SharesJanuary 1, 2025 | insidertrades.comAlan J. Russell Sells 100,000 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Alan J. Russell sold 100,000 shares of the company's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $27.37, for a total transaction of $2,737,000.00. Following the completion of the transaction, the insider now directly owns 14,863 shares of the company's stock, valued at $406,800.31. This represents a 87.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.December 31, 2024 | marketbeat.comEdgewise: Remains A Buy After Latest Becker Muscular Dystrophy DataDecember 31, 2024 | seekingalpha.comFranklin Resources Inc. Acquires 20,674 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Franklin Resources Inc. boosted its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 84.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,223 shares of the company's stock afDecember 29, 2024 | marketbeat.comMarc Semigran Sells 29,709 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Marc Semigran sold 29,709 shares of the business's stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $29.69, for a total value of $882,060.21. Following the sale, the insider now owns 6,716 shares of the company's stock, valued at $199,398.04. The trade was a 81.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.December 27, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 2.5% - Here's What HappenedEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 2.5% - Time to Sell?December 24, 2024 | marketbeat.comGeode Capital Management LLC Has $42.70 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Geode Capital Management LLC cut its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,599,535 shares of the company's stock after selling 73,118 shares durDecember 24, 2024 | marketbeat.comBarclays PLC Increases Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Barclays PLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 291.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,350 shares of the company's stock afDecember 24, 2024 | marketbeat.comState Street Corp Has $44.98 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)State Street Corp boosted its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,685,115 shares of the company's sDecember 20, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for EWTX EarningsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of Edgewise Therapeutics in a research note issued on Monday, December 16th. Leerink Partnrs analyst J. Schwartz now anticipates thatDecember 19, 2024 | marketbeat.comShort Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2%Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 5,740,000 shares, a decline of 10.2% from the November 15th total of 6,390,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 9.2% of the company's stock are sold short.December 17, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $50.00Evercore ISI boosted their target price on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Tuesday.December 17, 2024 | marketbeat.comEdgewise Therapeutics price target raised to $50 from $44 at LeerinkDecember 17, 2024 | markets.businessinsider.comBuy Rating for Edgewise Therapeutics Driven by Promising CANYON Trial ResultsDecember 17, 2024 | markets.businessinsider.comWellington Management Group LLP Lowers Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Wellington Management Group LLP reduced its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 58.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 205,321 shares ofDecember 17, 2024 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Buy" by AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among brokerages thaDecember 17, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading Volume - What's Next?Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading Volume - Time to Buy?December 16, 2024 | marketbeat.comEdgewise Therapeutics Shares Higher on Positive Trial ResultsDecember 16, 2024 | marketwatch.comPepGen stock craters 35% on FDA clinical holdDecember 16, 2024 | msn.comEdgewise Therapeutics Announces Positive Topline Results From CANYON Phase 2 Trial Of SevasemtenDecember 16, 2024 | markets.businessinsider.comEdgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)December 16, 2024 | businesswire.com28,303 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by XTX Topco LtdXTX Topco Ltd purchased a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 28,303 shares of the company's stock, valued at approximately $December 12, 2024 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Position Lessened by Fmr LLCFmr LLC trimmed its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 86.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 653,208 shares of the company's stock after selling 4,127,355December 11, 2024 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. decreased its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 24.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,832,867 shares of the company'sDecember 10, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Cuts Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Charles Schwab Investment Management Inc. lowered its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 522,086 shares of the company's sDecember 9, 2024 | marketbeat.comEdgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease ResearchDecember 5, 2024 | finance.yahoo.comEdgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease ResearchDecember 5, 2024 | businesswire.comPolar Asset Management Partners Inc. Has $4.21 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Polar Asset Management Partners Inc. cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 16.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 157,579 shares of the company's stock after selling 29December 5, 2024 | marketbeat.comJanus Henderson Group PLC Has $121.62 Million Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Janus Henderson Group PLC boosted its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 74.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,558,519 shares of the company's stock afDecember 5, 2024 | marketbeat.comGlenmede Trust Co. NA Acquires Shares of 18,085 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Glenmede Trust Co. NA acquired a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 18,085 shares of the company's stock, valued at approxDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $17.54 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Parkman Healthcare Partners LLC increased its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 14.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 657,070 shares of the company's stock after buying an adDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)HighVista Strategies LLC purchased a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 88,838 shares of the company's stock, valuDecember 3, 2024 | marketbeat.comFred Alger Management LLC Purchases New Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Fred Alger Management LLC acquired a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 21,128 shares of the company's stoDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Buys New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Intech Investment Management LLC purchased a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,900 shares of the cDecember 2, 2024 | marketbeat.comWalleye Capital LLC Invests $6.47 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Walleye Capital LLC acquired a new position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 242,251 shares of the company's stock, valued atDecember 1, 2024 | marketbeat.comBraidwell LP Makes New $52.27 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Braidwell LP acquired a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,958,310 shares of the company's stock, valued at approximately $52,267November 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Buys Shares of 187,695 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Ally Bridge Group NY LLC purchased a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 187,695 shares of the company's stock, valued at approxNovember 28, 2024 | marketbeat.comAcuta Capital Partners LLC Invests $1.68 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Acuta Capital Partners LLC acquired a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 63,000 shares of the company's stock, valued at approximately $1,681,000. EdNovember 28, 2024 | marketbeat.com Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Media Mentions By Week EWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EWTX News Sentiment▼0.490.44▲Average Medical News Sentiment EWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EWTX Articles This Week▼84▲EWTX Articles Average Week Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Blueprint Medicines News Today BridgeBio Pharma News Today Legend Biotech News Today Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EWTX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EWTX Stock Alerts